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Abstract
Cancer drug expenditures have been increasing significantly in countries around the world. A recent paper in the
IJHPR provides new knowledge and insights into this global phenomenon by analyzing how it is playing out in an
Israeli health plan with over two million members, whose state-of-the-art information systems provide an
opportunity to explore these changes in a comprehensive, detailed and reliable manner. There is a wide variation in
both the cost-effectiveness and the budget impact of individual drugs. These issues also vary when analyzing drugs
in other countries due to differential pricing mechanisms. In addition to drug expenditure, the overall cost of
cancer care is increasing, partly due to expenditures on non-pharmacologic treatments and diagnostic testing. With
the arrival of new therapies, the future of cancer care is exciting. However, there will be many challenges ahead
with regard to the ability to pay for such innovations. In this commentary we discuss the current problems and
anticipate the future challenges.
Background
Cancer drug costs have become a major concern in policy
discussions and in the mainstream media. The costs of
cancer care are not only challenges for governments, and
insurance companies, but they are increasingly placing a
financial burden on patients. Lomnicky et al. have demon-
strated the significant increase in expenditure on cancer
drugs by Maccabi Healthcare Services, an Israeli health
plan which insures more than two million people. This
health plan has state-of-the-art information systems which
provide a unique opportunity to explore these changes in
a comprehensive, detailed and reliable manner, for a large
and relatively stable population over a long period of time.
Conversely they have demonstrated that expenditure on
cardiac drugs has decreased while drug expenditure for
non cardiac or non-cancerous diseases has remained rela-
tively constant [1]. These data provoke many thoughts
and questions regarding cancer drug costs. Why is the ex-
penditure on cancer drugs increasing? Are we getting
value for money? How significant is this increase when
considering the whole healthcare budget? How does Israel
fare compared to other countries in the world regarding
cancer drug costs? What does the future hold, and will
this expenditure continue to grow? Will the movement to-
wards personalized therapy, using genetic testing with tar-
geted therapy lead to an increase or decrease in
expenditure? In this commentary we will attempt to an-
swer these questions.
Cost versus value
Understanding costs is important especially when
working within a fixed budget. However, perhaps the
more important question is cost-effectiveness or value.
Paying 12,000 shekels (approximately $3000) for a month
of drug treatment may sound a lot, however if this cures a
deadly disease, we can consider it to be highly cost-
effective. On the other hand, paying the same amount for a
drug that increases life expectancy by just 6 to 12 weeks is
totally different, and would not be considered cost-effective
by most conventional thresholds. To explore this issue, it is
worth considering diseases aside from cancer. Although
the recent introduction of drugs to treat hepatitis C came
at a high price tag, the efficacy is tremendous, with the
potential to cure the disease. There are significant
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differences in prices around the world, but in the US, a
12 week course of sofosbuvir costs approximately $65,000
[2]. Despite such high prices in the US, such drugs have
been demonstrated to be cost-effective due to the signifi-
cant benefit to patients [3].
In contrast, bevacizumab is used in colorectal cancer and
increases life expectancy by only about 6 weeks. In Israel
this costs approximately 12,000 shekels per month, while in
the United States it costs approximately $5300 per month.
Based on prices in the US, this treatment is not considered
cost-effective by all conventional thresholds – although its
use is widespread [4]. Despite many advances in the man-
agement of cancer, the drugs required come at high prices,
and the duration of therapy is often extensive. For example,
the development of pertuzumab has been hailed as a major
achievement in the ability to treat HER2 positive breast
cancer. However, given the high cost (approx. $215,000 per
patient [5]), it has also been demonstrated not to be cost-
effective in metastatic disease, based on US prices [5]. Many
drugs used in the metastatic setting (stage 4/advanced) may
have low cost-effectiveness given that they extend life by
just a matter of weeks. However, drugs used in the
adjuvant setting (early stage/curative), may be much more
cost-effective given the potential for cure. Such drugs are
used to decrease the chance of disease recurrence following
surgery, and thus often convey a significant clinical benefit.
The patient’s perspective or the healthcare
system’s perspective?
When considering healthcare costs, traditionally the area
of greatest focus has been the perspective of the institu-
tional payer such as governments or insurance companies.
However we are increasingly learning that the patients’
perspective is important to consider with regard to the
financial burden that they incur related to treatment.
Recent research from Washington State has demonstrated
that people with a diagnosis of cancer have a 2.7 times
higher risk of bankruptcy, than people without cancer [6].
However, the story does not stop there. Patients who
declared bankruptcy had a 79 % greater mortality risk than
patients who had not declared bankruptcy, suggesting that
significant financial distress has a negative impact on
health outcomes [7]. These financial problems in the
United States are largely related to cost-sharing, with high
deductibles and copays. One may argue that this is not a
concern within the public system in Israel and other
countries with universal health care coverage. However,
we would propose that many patients in Israel take on
considerable financial burden as a result of payments for
second opinions, additional tests, and drugs not included
within the basket of services. So while the cost-sharing is
not a major problem for drugs in the basket, it is a prob-
lem when patients decide to do additional tests and treat-
ments not included in the basket.
Even more significantly, growing expenditures on cancer
drugs can crowd out funding for other important medica-
tions and/or other treatments. This is most obvious in coun-
tries like Israel that explicitly set aside a certain amount of
money each year for the funding of new technologies [8],
forcing explicit prioritization and head-to-head comparisons
of candidates for addition to the benefits package – taking
into account both costs and benefits. But even in countries
without annual budget caps for new technologies, overall
health care resources are typically limited and budget con-
strained, so that increased expenditures on cancer drugs can
ultimately come at the expense of treatment for a wide
range of significant threats to population health, including
heart disease, mental health, arthritis, and dementia. While
this does not imply that increased spending on cancer drugs
is necessarily a bad thing, it does suggest that the health
benefits of such increases need to be weighed against the
benefits to be gained from alternative uses of the funds.
Global variations in drug prices
Drug prices and accessibility vary significantly around the
world. While some drugs within Europe have equivalent
prices in different countries due to “reference pricing” [9],
many drugs carry higher price tags in the United States
[10, 11]. However, understanding the actual amount of
money that changes hands is a major challenge. Many
different programs of negotiations exist between countries
and within countries, including programs for risk sharing,
discounting and rebates. The details of such programs are
often a high level secret, thus reducing transparency and
the ability to truly understand value.
Are drugs the only topic of concern in the cost of
cancer care?
While the high cost of cancer drugs has received a lot of
attention recently, it is important to put this expenditure
into perspective. In the United States, drug spending
constitutes approximately 20 % of total cancer spending
for commercially insured individuals [12]. However it is
important to recognize that cancer drug spending is a
growing sector within health spending, and thus warrants
scrutiny. It is also important to consider that there is great
expenditure in other fields of cancer care, including
radiology, radiation oncology, surgery, molecular diagnos-
tics and costly interventions at the end of life. Within
these fields and others, there are definitely areas of low
value care, where efficiency could be improved. We
believe that it is important to maintain a focus on high
quality, high value care throughout all fields of medicine.
The future: targeted therapy, immunotherapy and
biosimilars
Lomnicky et al. have demonstrated that cancer drug
expenditure has increased in the previous decade, but
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what can we expect in the next decade? The world of
cancer care is entering an exciting era, with the arrival
of immunotherapy and the further development of treat-
ment tailored specifically to the genetic makeup of an
individual’s tumor. Drugs such as nivolumab and pem-
brolizumab inhibit the programmed cell death protein 1
(PD-1) on tumors and thus “remove the brakes” for an
individual’s immune system to fight against a tumor.
Such drugs have already gained approval in the manage-
ment of melanoma, lung and kidney cancer, with more
approvals expected in the coming months and years
[13–16]. These drugs can also be paired with cytotoxic
T-lymphocyte-associated protein 4 (CTLA4) inhibitors
such as ipilumumab, thus stimulating the immune system
by two separate mechanisms. While many patients do not
gain any benefit from such drugs, a small proportion may
gain durable responses, with the potential for major
survival benefits, never before seen in these and other
malignancies. Targeted therapy is also holding great prom-
ise and lung cancer therapy is the poster child for this
field. Patients with this disease now undergo genetic test-
ing of their tumors to evaluate for EGFR mutations or
ALK translocations in order to treat with either class of
drugs for both mutations and alterations [17, 18]. Despite
subsequent resistance that usually develops, further 2nd
generation tyrosine kinase inhibitors have been developed
to target the resistant mutations. These include ceritinib
and osimertinib [19, 20]. It is expected that new targeted
therapies will be developed in the coming years in all fields
of cancer. Although the advances in immunotherapy and
targeted therapy are exciting, the costs will pose a major
challenge, particularly as combination therapies are intro-
duced. It is likely that risk-sharing will be required in
order to fund such interventions.
After patent expiry we have traditionally seen major
decreases in drug prices following the arrival of generic
drugs. This has been of major importance for the bud-
gets of healthcare payers. However a major challenge is
to be expected in the coming years related to biologic
therapies. Many new cancer drugs are biological agents,
and only biologically similar agents can be produced
following patent expiration. Regulatory agencies have
required that such biosimilar drugs go through basic
testing to demonstrate pharmacological equivalency,
however stringent clinical trials are not required. Despite
this, however, the cost of development of such biosimilar
drugs is considered to be higher than the development
of generic drugs. As a result, the drug price reductions
at patent expiration are not expected to be significantly
less than those for generic drugs, however this may also
be simply because of a lack of significant competition.
Generic drug prices have traditionally fallen to around
10 % of their original price. However biosimilar drug
prices are projected initially to fall only to approximately
80 %. As a result, it is expected that drug budgets may
face significant challenges in the future.
Conclusions
There is much excitement about new developments in the
field of cancer care. While some of these developments
hold great promise, many new drugs confer only a minimal
level of clinical benefit. Scientists, society and policy makers
will be increasingly challenged with decisions of how to
spend finite resources. Clear definitions and understanding
of both cost-effectiveness and budget impact are essential
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